<DOC>
	<DOCNO>NCT00500604</DOCNO>
	<brief_summary>The primary objective compare efficacy irbesartan/hydrochlorothiazide 300/25mg valsartan/hydrochlorothiazide 160/25mg reduce mean systolic blood pressure ( SBP ) measure home blood pressure monitoring ( HBPM ) 24 week compare baseline . The secondary objective : - To compare percentage patient normal blood pressure measure HBPM doctor 's office week 16 24 - To compare difference mean Diastolic Blood Pressure ( DBP ) , mean morning even SBP DBP evaluate HBPM week 16 24 - To compare difference mean SBP evaluate HBPM week 16 - To compare difference mean SBP DBP evaluate doctor 's office week 16 24 - To determine incidence severity adverse event</brief_summary>
	<brief_title>Efficacy Irbesartan/Hydrochlorothiazide Versus Valsartan/Hydrochlorothiazide Mild Moderate Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Irbesartan</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<criteria>Established essential hypertension , untreated treat uncontrolled treatment : Office SBP ≥ 160 mmHg untreated patient Office SBP ≥ 140 mmHg patient already treat antihypertensive drug . Previous antihypertensive therapy must implement minimum 4 week must either monotherapy one follow permit combination drug : ACE inhibitor / calcium channel blocker Beta blocker / calcium channel blocker Beta blocker / low dose diuretic ACE inhibitor / low dose diuretic SBP ≥ 180 mmHg and/or DBP ≥ 110 mmHg evaluate doctor 's office Visit 1 Known suspect cause secondary hypertension Patient bilateral renal artery stenosis , renal artery stenosis solitary kidney , renal transplant one functioning kidney Type 1 diabetes mellitus Significant cardiovascular , neurological , endocrine , renal , metabolic , gastrointestinal disease , malignancy disease consider Investigator make participation study best interest subject Known hypersensitivity diuretic sulphonamides history angioedema cough relate administration angiotensin II receptor antagonist combination drug use Known contraindication study drug Concomitant use antihypertensive treatment Use investigational product study within 3 month prior study Inability obtain valid HBPM recording i.e. , obesity , arm circumference &gt; 32 cm arrhythmia Administration investigational drug last 30 day enrolment course study Pregnant breastfeed woman Women childbearing potential protected effective contraceptive method birth control and/or unwilling unable test pregnancy The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2010</verification_date>
</DOC>